{
  "experiment_id": "exp_05",
  "experiment_name": "PSR-Hybrid Parity Approach",
  "timestamp": "2025-11-03T22:30:45.421622",
  "script": "experiments/novo_parity/scripts/exp_05_psr_hybrid_parity.py",
  "input_files": [
    "data/test/jain/processed/jain_ELISA_ONLY_116.csv",
    "data/test/jain/processed/jain_sd03.csv"
  ],
  "output_file": "experiments/novo_parity/datasets/jain_86_exp05.csv",
  "method": {
    "step_1": "Reclassify 5 specific \u2192 non-specific",
    "step_2": "Remove top 30 specific by composite risk"
  },
  "parameters": {
    "psr_flip_threshold": 0.4,
    "composite_risk_formula": "PSR_norm + AC-SINS_norm + HIC_norm + (1 - Tm_norm)",
    "tier_a_rationale": "ELISA=0 but PSR >0.4 (polyreactivity missed by ELISA)",
    "tier_b_rationale": "61% ADA (NEJM) + aggregation + chimeric"
  },
  "reclassified_ids": {
    "tier_a_psr_based": [
      {
        "id": "bavituximab",
        "psr": 0.5570368731420577,
        "reason": "Tier A: PSR=0.557 >0.4 despite ELISA=0"
      },
      {
        "id": "bimagrumab",
        "psr": 0.6965555618675863,
        "reason": "Tier A: PSR=0.697 >0.4 despite ELISA=0"
      },
      {
        "id": "ganitumab",
        "psr": 0.5528448378515598,
        "reason": "Tier A: PSR=0.553 >0.4 despite ELISA=0"
      },
      {
        "id": "olaratumab",
        "psr": 0.4831425745388005,
        "reason": "Tier A: PSR=0.483 >0.4 despite ELISA=0"
      }
    ],
    "tier_b_clinical": [
      {
        "id": "infliximab",
        "reason": "Tier B: 61% ADA (NEJM) + aggregation + chimeric"
      }
    ]
  },
  "removed_ids": [
    "lirilumab",
    "basiliximab",
    "glembatumumab",
    "urelumab",
    "drozitumab",
    "tremelimumab",
    "nimotuzumab",
    "pembrolizumab",
    "atezolizumab",
    "ipilimumab",
    "ocrelizumab",
    "tralokinumab",
    "rituximab",
    "eldelumab",
    "fezakinumab",
    "tigatuzumab",
    "seribantumab",
    "dinutuximab",
    "enokizumab",
    "lumiliximab",
    "bevacizumab",
    "benralizumab",
    "siltuximab",
    "tabalumab",
    "nivolumab",
    "lebrikizumab",
    "crenezumab",
    "galiximab",
    "veltuzumab",
    "tovetumab"
  ],
  "counts": {
    "step_0_start": {
      "total": 116,
      "specific": 94,
      "non_specific": 22
    },
    "step_1_after_reclassification": {
      "total": 116,
      "specific": 89,
      "non_specific": 27
    },
    "step_2_final": {
      "total": 86,
      "specific": 59,
      "non_specific": 27
    }
  },
  "validation": {
    "target_distribution": "59 specific / 27 non-specific = 86 total",
    "achieved": "\u2705 EXACT MATCH"
  }
}